Avicanna Reports Q2 2024
Provided By GlobeNewswire
Last update: Aug 14, 2024
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023
Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain
Provided By GlobeNewswire
Last update: Aug 14, 2024
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023
Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain
